Longeveron (LGVN) announced the appointment of Nataliya Agafonova, M. D., as the Company’s Chief Medical Officer, CMO, effective as of July 1, 2023. As CMO, Dr. Agafonova will lead Longeveron’s global clinical development and regulatory strategy for the Company’s investigational products. Dr. Agafonova joins Longeveron from Otsuka Pharmaceutical (OTSKY), where she served as Clinical Development Lead, Senior Medical Director, and Product Development Chair.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LGVN: